Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Cited by Google
- Similars in SciELO
- Similars in Google
Share
Revista Colombiana de Nefrología
On-line version ISSN 2500-5006
Abstract
RICO FONTALVO, Jorge et al. New evidence in the treatment of diabetic kidney disease: what is finerenone’s contribution?. Rev. colom. nefrol. [online]. 2022, vol.9, n.3, 302. Epub Jan 01, 2023. ISSN 2500-5006. https://doi.org/10.22265/acnef.9.3.603.
Background:
Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease (CKD) worldwide and has a direct impact on cardiovascular risk and mortality in patients with diabetes mellitus (DM). Finerenone, a selective mineralocorticoid receptor (MRA) antagonist, has been described in several recent studies as a drug that contributes to slowing the progression of CKD and reducing cardiovascular risk, with an adequate safety profile.
Purpose:
To carry out a review of the literature on the impact of finerenone on the progression of renal damage and cardiovascular risk in patients with DKD.
Methodology:
A systematic search were carried out in various sources: PubMed (Medline, United States Library of Congress), Science Direct, Scopus, Embase and Lilacs; the search was restricted to references in Spanish and English, with no limits on publication date. The following keywords in the English language were used: diabetic renal disease, chronic kidney disease, diabetes mellitus, spironolactone, eplerenone, finerenone, mineralocorticoid receptor antagonist and their corresponding Spanish versions.
Results:
The references found in the search were reviewed among the different authors to subsequently proceed to prepare the document.
Conclusions:
Finerenone is a drug that provides cardio and nephroprotection in patients with DKD albuminuric phenotype.
Keywords : Finerenone; Diabetic Kidney Disease; Mineralocorticoid Antagonist; Spironolactone; Eplerenone; Diabetes Mellitus..